CSS
CRVS icon

Cubist Systematic Strategies’s Corvus Pharmaceuticals CRVS Stock Holding History

Cubist Systematic Strategies’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,026
Closed -$52.9K – 3070
2024
Q3 		$52.9K Sell
10,026
-14,338
-59% -$51.5K ﹤0.01% 2760
2024
Q2 		$44.3K Buy
+24,364
New +$45.4K ﹤0.01% 2716
2023
Q3 		– Sell
-15,552
Closed -$35.6K – 3437
2023
Q2 		$35.6K Buy
+15,552
New +$32.3K ﹤0.01% 3135
2022
Q2 		– Sell
-6,600
Closed -$11K – 4386
2022
Q1 		$11K Sell
6,600
-16,645
-72% -$30.5K ﹤0.01% 3493
2021
Q4 		$56K Buy
23,245
+3,193
+16% +$12.4K ﹤0.01% 3295
2021
Q3 		$97K Buy
+20,052
New +$59.4K ﹤0.01% 2748
2017
Q4 		– Sell
-1,914
Closed -$31K – 1937
2017
Q3 		$31K Buy
+1,914
New +$26.5K ﹤0.01% 1756
2017
Q2 		– Sell
-1,429
Closed -$30K – 1707
2017
Q1 		$30K Buy
1,429
+901
+171% +$14.1K ﹤0.01% 1523
2016
Q4 		$8K Buy
+528
New +$8.03K ﹤0.01% 1660

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Cubist Systematic Strategies's CRVS Position: Q4 2024 in Review

Cubist Systematic Strategies sold out of Corvus Pharmaceuticals (CRVS) in Q4 2024, closing a stake of 10,026 shares — an estimated $52.9K sold.

Cubist Systematic Strategies first reported a position in CRVS in Q4 2016 and held it in 9 quarters. The position peaked at $97K in Q3 2021. 85 funds tracked by Wall St. Rank hold CRVS as of Q4 2024.

  • Cubist Systematic Strategies reported no remaining Corvus Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 10,026 Corvus Pharmaceuticals shares in Q4 2024, an estimated $52.9K.
  • Cubist Systematic Strategies first reported a position in Corvus Pharmaceuticals in Q4 2016 and held it in 9 quarters.
  • Cubist Systematic Strategies's Corvus Pharmaceuticals position peaked at $97K in Q3 2021.
  • 85 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q4 2024.

Based on Cubist Systematic Strategies's 13F filing for Q4 2024, filed 14 Feb 2025.